
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1019 | 920 | 1072 | 964 | 1234 | 1375 |
Fund Return | 1.94% | -8% | 7.16% | -1.21% | 4.29% | 3.24% |
Place in category | 1352 | 1350 | 1301 | 1502 | 998 | 618 |
% in Category | 64 | 65 | 63 | 84 | 65 | 66 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Manulife Global Asia REIT AA G | 298.06M | -12.46 | -9.79 | - | ||
Manulife Global Fund Global Equity | 233.29M | 0.28 | 5.64 | 6.31 | ||
Manulife Glbl Fund Asian Eq I3 USD | 100.53M | 0.86 | 4.06 | - | ||
Manulife Glbl Fund Asian Eq Fund I | 100.53M | -0.29 | 1.16 | 3.52 | ||
Manulife Glbl Fund Asian Eq Fund AA | 100.53M | -0.49 | 0.36 | 2.78 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
GS S GS Europe CORE Equity Portfolu | 3.17B | 11.00 | 7.66 | 6.27 | ||
Europe Equity Plus Fund A perf acc | 2.52B | 12.15 | 10.47 | 6.41 | ||
JPMorgan InVs Euro SelectEqA AccUSD | 2.1B | 10.66 | 5.99 | 4.96 | ||
JPMorgan InVs Euro SelectEqD AccUSD | 2.1B | 10.45 | 5.17 | 4.17 | ||
JPEurope Equity Plus Fund C perf ac | 2.52B | 6.26 | 7.88 | 6.92 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Novo Nordisk B | DK0062498333 | 5.73 | 436.6 | +0.17% | |
ASML Holding | NL0010273215 | 4.99 | 602.90 | +2.19% | |
AstraZeneca | GB0009895292 | 3.80 | 10,252.0 | -0.66% | |
SAP | DE0007164600 | 3.66 | 230.075 | +0.56% | |
Unilever | GB00B10RZP78 | 2.86 | 54.84 | +0.55% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Neutral | Buy | Buy |
Technical Indicators | BUY | Strong Sell | BUY |
Summary | Neutral | Neutral | Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review